Clinical Complications, Mortality, and Healthcare Resource Utilization of Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in Ontario, Canada: A Retrospective Cohort Study
Advances in Therapy · 2026
DOI: 10.1007/s12325-025-03411-4 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Advances in Therapy, 2026. Verfasst von Lauren Lilly und 8 weiteren Autor:innen. Beteiligte Einrichtung: Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA, 02210, USA. Lauren_lilly@vrtx.com. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Patient Acceptance of Health Care, Priapism, Acute Chest Syndrome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Vertex Pharmaceuticals.
Abstract (Originalsprache)
INTRODUCTION: Sickle cell disease (SCD) is characterized by vaso-occlusive crises (VOCs) that can lead to clinical complications, higher mortality, and healthcare resource use (HCRU). Lack of Canadian data poses challenges to health system planning, a gap this study intends to close. We analyzed clinical complications, mortality, and HCRU in patients with SCD with recurrent VOCs in Canada. METHODS: This retrospective cohort study identified patients with SCD with recurrent VOCs from the Institute for Clinical Evaluative Sciences (ICES) databases in Ontario, Canada from January 1, 2010, to December 31, 2021. VOCs were defined as SCD with crisis, priapism, or acute chest syndrome. Patients were matched (1:3) by age, sex, and geographic area with non-SCD individuals in the general population. Clinical complications, mortality, and HCRU were analyzed. RESULTS: Eight hundred fifty-nine patients with SCD with recurrent VOCs were identified and matched to 2577 controls. Mean (standard deviation [SD]) age was 22.1 (14.4) years; 50.9% were female. Mean (SD) rate of VOCs per person per year was 3.2 (4.4) in patients with recurrent VOCs. Acute and chronic complication rates were higher in patients than controls. Compared with controls, mortality was substantially higher for patients with recurrent VOCs. Mean (SD) age at death for patients with recurrent VOCs was 39.2 (17.2) years. There was significantly higher HCRU than matched controls (P < 0.0001). CONCLUSION: Patients with SCD with recurrent VOCs had substantially higher rates of complications, mortality, and HCRU than controls, further highlighting the need for novel therapies to reduce VOCs and the associated burden.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA, 02210, USA. Lauren_lilly@vrtx.com.
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA, 02210, USA.
- IQVIA Solutions Canada Inc, Kanata, ON, Canada.
- University of Toronto, Toronto, ON, Canada.
ORCID-Profile: Lauren Lilly
Förderung
- Vertex Pharmaceuticals
Zitieren
APA
Lilly, L., Udeze, C., Nightingale, N., Wang, I., Murray, J., Penaranda, C., Neish, C. S., Li, N., & Kuo, K. H. M. (2026). Clinical Complications, Mortality, and Healthcare Resource Utilization of Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in Ontario, Canada: A Retrospective Cohort Study. Advances in Therapy. https://doi.org/10.1007/s12325-025-03411-4
Vancouver
Lilly L, Udeze C, Nightingale N, Wang I, Murray J, Penaranda C, et al. Clinical Complications, Mortality, and Healthcare Resource Utilization of Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in Ontario, Canada: A Retrospective Cohort Study. Advances in Therapy. 2026. doi:10.1007/s12325-025-03411-4
BibTeX
@article{Lilly2026,
author = {Lilly, Lauren and Udeze, Chuka and Nightingale, Natalie and Wang, Irene and Murray, Jillian and Penaranda, Carlos and Neish, Calum S and Li, Nanxin and Kuo, Kevin H M},
title = {Clinical Complications, Mortality, and Healthcare Resource Utilization of Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in Ontario, Canada: A Retrospective Cohort Study},
journal = {Advances in Therapy},
year = {2026},
doi = {10.1007/s12325-025-03411-4}
}
EUVIMED